Platinum-based chemotherapy in childhood causes mutations that age the liver — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- A study published in Science found that children treated for hepatoblastoma with platinum-based chemotherapy carried an average of 2,200 mutations per healthy liver sample, a burden that makes pediatric liver tissue resemble adult liver tissue at the molecular level.
- Researchers used NanoSeq DNA sequencing to compare liver, tumor, and blood tissue from treated children against untreated controls and fetal liver tissue, establishing that mutation counts rose in proportion to platinum exposure — patients given both cisplatin and carboplatin accumulated more mutations than those given cisplatin alone.
- Foad Rouhani of King's College London, one of the study's authors, noted that the mutation pattern included cancer genes as well as genes linked to long-term liver metabolism changes, but stressed the findings show only potential for future disease, not certainty of cancer.
- Liver cells sustained far more mutations than blood cells in the same patients despite platinum chemotherapy being a systemic treatment, a disparity the authors say could reflect either liver-specific metabolism of the drug, weaker DNA repair in liver cells, or a pre-existing vulnerability that explains why the liver became cancerous in the first place.
- Sanjeev Vasudevan and Donald Williams Parsons of Baylor College of Medicine, writing in a perspective piece accompanying the study, called the findings strong evidence for survivorship studies tracking hepatoblastoma patients past their third decade of life.
- Platinum-based chemotherapy transformed hepatoblastoma outcomes, lifting five-year survival for localized tumors from roughly 20% to over 80%, which is why the researchers framed their work as a call for closer lifelong monitoring of survivors rather than a reason to abandon these drugs.
- Rouhani said the long-term goal is mechanistic understanding sufficient to design next-generation chemotherapies that kill cancer cells while leaving healthy tissue largely untouched.
Why it matters: Platinum-based chemotherapy has made hepatoblastoma, the most common childhood liver cancer, survivable for most patients with localized tumors — but the same drugs that saved them are leaving an adult-scale mutational footprint in their healthy liver tissue. Roughly 2,200 mutations per liver sample, concentrated in cancer genes and metabolic genes, means pediatric oncologists now have a concrete biological reason to build lifelong monitoring protocols for survivors rather than treating cure as the endpoint.
Ask SkimNews
